{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T23:59:01Z","timestamp":1785369541966,"version":"3.55.0"},"reference-count":17,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Endocrinology and Metabolism Clinics of North America"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.ecl.2026.04.011","type":"journal-article","created":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T11:26:28Z","timestamp":1779276388000},"page":"563-572","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Expectations and Experiences"],"prefix":"10.1016","volume":"55","author":[{"given":"Julie Keller","family":"Heverly","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"14","key":"10.1016\/j.ecl.2026.04.011_bib1","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1056\/NEJM199309303291401","article-title":"The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes Mellitus","volume":"329","year":"1993","journal-title":"N Engl J Med"},{"issue":"8","key":"10.1016\/j.ecl.2026.04.011_bib2","doi-asserted-by":"crossref","first-page":"1378","DOI":"10.2337\/dc15-2399","article-title":"Mortality in type 1 diabetes in the DCCT\/EDIC versus the general population","volume":"39","year":"2016","journal-title":"Diabetes Care"},{"key":"10.1016\/j.ecl.2026.04.011_bib3","article-title":"Global type 1 diabetes prevalence, incidence, and mortality estimates 2025: results from the international diabetes federation Atlas, 11th Edition, and the T1D index version 3.0","volume":"225","year":"2025","journal-title":"Diabetes Res Clin Pract"},{"issue":"6","key":"10.1016\/j.ecl.2026.04.011_bib4","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1089\/dia.2019.0027","article-title":"Adjunct therapy in type 1 diabetes: a survey to uncover unmet needs and patient preferences beyond HbA1c measures","volume":"21","author":"Pettus","year":"2019","journal-title":"Diabetes Technol Ther"},{"key":"10.1016\/j.ecl.2026.04.011_bib5","article-title":"Can unmet needs Be addressed by adjunctive therapies? Findings from a patient perspectives survey in adults with type 1 diabetes","volume":"11","author":"Lamaro","year":"2024","journal-title":"J Patient Exp"},{"issue":"6","key":"10.1016\/j.ecl.2026.04.011_bib6","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1007\/s13300-025-01735-6","article-title":"The urgent need for breakthrough therapies and a world without type 1 diabetes","volume":"16","author":"Starr","year":"2025","journal-title":"Diabetes Ther"},{"issue":"3","key":"10.1016\/j.ecl.2026.04.011_bib7","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1007\/s00125-008-1238-y","article-title":"Ghrelin-producing epsilon cells in the developing and adult human pancreas","volume":"52","author":"Andralojc","year":"2009","journal-title":"Diabetologia"},{"issue":"1","key":"10.1016\/j.ecl.2026.04.011_bib8","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1007\/s00125-003-1258-6","article-title":"Abnormal ghrelin secretion in new onset childhood Type 1 diabetes","volume":"47","author":"Holdstock","year":"2004","journal-title":"Diabetologia"},{"issue":"2","key":"10.1016\/j.ecl.2026.04.011_bib9","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1111\/j.1753-0407.2010.00074.x","article-title":"Distinctions between islet neogenesis and \u03b2-cell replication: implications for reversal of Type 1 and 2 diabetes","volume":"2","author":"Levetan","year":"2010","journal-title":"J Diabetes"},{"issue":"3","key":"10.1016\/j.ecl.2026.04.011_bib10","doi-asserted-by":"crossref","DOI":"10.1096\/fba.2024-00151","article-title":"The role of amylin, a gut\u2013brain axis hormone, in metabolic and neurological disorders","volume":"7","author":"Muhammad","year":"2025","journal-title":"FASEB BioAdvances"},{"issue":"3","key":"10.1016\/j.ecl.2026.04.011_bib13","doi-asserted-by":"crossref","first-page":"422","DOI":"10.3390\/jpm13030422","article-title":"Type 1 diabetes mellitus and autoimmune diseases: a critical review of the association and the application of personalized medicine","volume":"13","author":"Popoviciu","year":"2023","journal-title":"J Pers Med"},{"key":"10.1016\/j.ecl.2026.04.011_bib14","doi-asserted-by":"crossref","DOI":"10.1177\/20420188231180987","article-title":"Patient-perceived benefits and risks of off-label use of SGLT2 inhibitors and GLP-1 receptor agonists in type 1 diabetes: a structured qualitative assessment","volume":"14","author":"Edwards","year":"2023","journal-title":"Ther Adv Endocrinol Metab"},{"key":"10.1016\/j.ecl.2026.04.011_bib15","unstructured":"DiabetesMine d-data exChange. GLP-1 Therapy & Type 1 Diabetes Survey Report. 2025:1-6. Available at: https:\/\/drive.google.com\/file\/d\/1WD5LCh07-fbCKR1t3tdjkaojJiG1Zb3W\/view?usp=sharing (Accessed August 2025)."},{"issue":"1","key":"10.1016\/j.ecl.2026.04.011_bib16","doi-asserted-by":"crossref","first-page":"76","DOI":"10.2337\/cd22-0067","article-title":"Factors associated with improved A1C among adults with type 1 diabetes in the United States","volume":"41","author":"Akturk","year":"2023","journal-title":"Clin Diabetes Publ Am Diabetes Assoc"},{"key":"10.1016\/j.ecl.2026.04.011_bib17","article-title":"Real-world evidence of the effect of adjunctive semaglutide on weight change, glycemic control, and metabolic dysfunction-associated steatotic liver disease in people with type 1 diabetes","author":"Mertens","year":"2025","journal-title":"Diabetes Technol Ther"},{"issue":"8","key":"10.1016\/j.ecl.2026.04.011_bib18","doi-asserted-by":"crossref","DOI":"10.1056\/EVIDoa2500173","article-title":"Semaglutide in adults with type 1 diabetes and obesity","volume":"4","author":"Shah","year":"2025","journal-title":"NEJM Evid"},{"issue":"50","key":"10.1016\/j.ecl.2026.04.011_bib19","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000046446","article-title":"Impact of semaglutide use on glycemic and metabolic profile in adults with type 1 diabetes having overweight or obesity: a systematic review and meta-analysis","volume":"104","author":"Dutta","year":"2025","journal-title":"Medicine (Baltimore)"}],"container-title":["Endocrinology and Metabolism Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889852926000320?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889852926000320?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T23:24:36Z","timestamp":1785367476000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0889852926000320"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":17,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["S0889852926000320"],"URL":"https:\/\/doi.org\/10.1016\/j.ecl.2026.04.011","relation":{},"ISSN":["0889-8529"],"issn-type":[{"value":"0889-8529","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Expectations and Experiences","name":"articletitle","label":"Article Title"},{"value":"Endocrinology and Metabolism Clinics of North America","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ecl.2026.04.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}